UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: September 17, 2013
(Date of earliest event reported)
SciClone Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-19825 | 94-3116852 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||
950 Tower Lane, Suite 900, Foster City, CA | 94404 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(650) 358-3456
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(d) On September 17, 2013, the Board of Directors (the “Board”) of SciClone Pharmaceuticals, Inc. (the “Company”), appointed Dr. Nancy T. Chang, Ph.D. to serve as a member of the Board, effective immediately. Dr. Chang’s term will expire at the 2014 annual meeting of stockholders, and she will be subject to the election of the Company’s stockholders at that meeting. Dr. Chang has also been appointed to serve on the Nominating and Governance Committee of the Company and the Business Development Committee of the Company, each effective as of her first day of service on the Board.
A copy of the Company’s press release announcing Dr. Chang’s appointment is attached asExhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | The following exhibits are filed herewith: |
| Exhibit 99.1 | Press release dated September 23, 2013. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: September 23, 2013 | SCICLONE PHARMACEUTICALS, INC. | |||
| By: | /s/ Wilson W. Cheung | |||
| Wilson W. Cheung | ||||
Chief Financial Officer and Senior Vice President, Finance | ||||
Exhibit Index
Exhibit No. | Description | |
| 99.1 | Press release dated September 23, 2013. | |